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1  | INTRODUC TION
Exogenous proteases derived from a variety of different species 
such as mites, fungi, and bacteria are constantly challenging the 
body‐own homeostasis and increasing the complexity of the prote‐
ase network. Allergens with protease activity can be a seasonal trig‐
ger for atopic diseases like allergic rhinitis or allergic asthma, and the 
constant exposure of perennial allergens can persistently aggravate 
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Abstract
Staphylococcus aureus is being recognized as a major cofactor in atopic diseases such 
as atopic dermatitis, chronic rhinosinusitis with nasal polyps, and asthma. The under‐
standing of the relationship between S aureus virulence factors and the immune sys‐
tem is continuously improving. Although the precise mechanism of the host's immune 
response adaptation to the variable secretion profile of S aureus strains continues to 
be a matter of debate, an increasing number of studies have reported on central ef‐
fects of S aureus secretome in allergy. In this review, we discuss how colonization of 
S aureus modulates the innate and adaptive immune response, thereby predisposing 
the organism to allergic sensitization and disrupting immune tolerance in the airways 
of patients with asthma and chronic rhinosinusitis with nasal polyps. Next, we pro‐
vide a critical overview of novel concepts dealing with S aureus in the initiation and 
persistence of chronic rhinosinusitis with nasal polyps and asthma. The role of the 
S aureus serine protease‐like proteins in the initiation of a type 2 response and the 
contribution of the IL‐33/ST2 signaling axis in allergic responses induced by bacterial 
allergens are discussed.
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the chronic inflammation.1 Recent studies have demonstrated that 
microbiota plays an essential role in fine‐tuning the immune re‐
sponse.2,3 S aureus became an important player in the type 2 biased 
immune responses in the airways.4,5 S aureus is a Gram‐positive, 
commensal organism with pathogenic properties. Over 30 percent of 
the human population are carriers of S aureus, harboring the bacteria 
either transiently or persistently in their nasal cavities.6 In the major‐
ity of human carriers, S aureus causes no detectable adverse effects. 
However, in patients with chronic rhinosinusitis with nasal polyps 
(CRSwNP), nasal colonization with S aureus and sensitization to S au-
reus enterotoxins are linked to a type 2 inflammatory response and 
asthma comorbidity.7 S aureus enterotoxin‐specific immunoglobulin 
E was shown to be functional independent of the atopic status of pa‐
tients.8,9 Importantly, S aureus enterotoxin sensitization is associated 
with allergic polysensitization in adolescents.10 Immunoproteomic 
analyses of the nasal polyps have identified detectable amounts of 
more than 600 S aureus proteins including α‐hemolysin, γ‐hemoly‐
sin, panton‐valentine leukocidin, S aureus toxins, and S aureus prote‐
ase‐like proteins (Spls).4,11	Furthermore,	Spls were shown to induce 
a specific immunoglobulin E (IgE) response in asthmatic patients.4
Moreover, S aureus contributes to the initiation of a type 2 im‐
mune response by fast induction of innate cytokines and chemok‐
ines from airway epithelial cells. In murine models of co‐exposure 
to Spls and ovalbumin (OVA), SplD breaks immune tolerance to the 
inert OVA, inducing the production of OVA‐specific IgE and strong 
airway inflammatory responses.5 Recently, it has been stressed that 
IL‐33 is a critical cytokine in allergic polysensitization and plays an 
essential role in an altered immune tolerance12 via activation of den‐
dritic cells13 and the induction of a type 2 immune response.14 S au-
reus induces an increase in IL‐33 protein levels in S aureus‐infected 
nasal polyp tissue.15 It has been shown that mice treated with SplD 
could initiate an IL‐33 mediated airway inflammation,5 supporting 
the role of S aureus‐secreted factors. This mechanism could substan‐
tially contribute to the development of a severe and difficult to con‐
trol	airway	disease	(Figure	1).
In the current review, we position Spls among other allergens 
with protease activity and provide a critical overview of emerging 
roles	 of	 Spls	 in	 a	 type	 2‐biased	 immune	 response.	 Finally,	we	 de‐
lineate the role of proteases in the activation of the IL‐33 signaling 
pathway,	which	is	upstream	of	a	type	2	inflammatory	response.	We	
F I G U R E  1   Induction of an allergic 
immune response by Staphylococcus 
aureus serine protease‐like protein D 
(SplD) in the airways. Airborne exposure 
to SplD causes a synergistic effect in 
allergic sensitization. SplD activates 
airway epithelial cells to release IL‐33, 
which acts via ST2 receptors on innate 
lymphoid cells type 2 (ILC2), T helper 
cells type 2 (Th2), dendritic cells. These 
events cause an amplification of adaptive 
immunity and production of type 2 
cytokines and result in reduced tolerance 
to allergens and aggravation of airway 
inflammation. Repeated exposures to 
SplD are associated with increased 
production of SplD‐specific and allergen‐
specific immunoglobulin E (IgE). SplD 
facilitates the production of mucus due 
to proliferation of goblet cells. Airway 
hyperreactivity is also increased after 
SplD exposure
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discuss how interventions with the IL‐33/ST2 signaling axis could 
modify allergic responses induced by bacterial allergens.
2  | E XOGENOUS PROTE A SES—SE A SONAL 
AND PERENNIAL ALLERGENS
2.1 | Airborne house dust mite allergens activate 
the airway epithelium
There are 24 groups of house dust mite (HDM) allergens out of 
which one comprises cysteine proteases and three groups are serine 
proteases. These proteases present a high IgE binding frequency, up 
to 100% in HDM allergic patients, and are thus major allergens.16 
Der p 1 alone can decrease the epithelial barrier by disrupting tight 
junctions and increase specific IgE production due to its proteolytic 
activity, cleaving the low‐affinity IgE receptor CD23, which leads to 
IgE upregulation, and the IL‐2 receptor CD25 on T cells resulting in a 
shift toward Th2 cell activation.17
Allergens with protease activity mediate their action through 
cleavage of a family of G protein–coupled receptors called protein‐
ase‐activated receptors (PARs). PAR2 is activated by cleavage of 
Der p 1.18 Toll‐like receptor 4 (TLR4), expressed on structural lung 
cells, was shown to interact with PAR2, strongly supporting the 
inflammatory response toward HDM.19 PAR2 activation by HDM 
is important for IgE formation; however, airway inflammation oc‐
curs independently of PAR2.20	 Furthermore,	 most	 allergens	 with	
protease activity (HDM, A alternata, cockroach) induce release of 
damage‐associated molecular patterns, such as IL‐33, thymic stro‐
mal lymphopoietin (TSLP), adenosine triphosphate, and IL‐1α, from 
epithelial cells in mice in vivo and airway epithelial damage.21‐23 
Furthermore,	HDM	as	well	as	the	cysteine	proteases	bromelain	and	
papain induce uric acid release while A alternata, Artemisia vulgaris, 
and Betula pendula extracts do not.24,25 This release of uric acid can 
further skew the T cell response toward a Th2 bias.23 The diminished 
response against heat‐inactivated or protease inhibitor–treated 
HDM allergens suggests that the proteolytic function is necessary 
for their allergenicity.24 The cysteine proteases of HDM seem to be 
more important for allergic sensitization than the serine proteases 
because the allergic response toward HDM extract with lower ser‐
ine protease activity was more pronounced than in extracts with 
higher activity.26
House dust mite induces an upregulation of IL‐33, triggering in‐
nate lymphoid cells type 2 (ILC2) and eosinophil recruitment to the 
lungs through RAGE‐dependent VCAM expression.24
Der p 1 can cleave IL‐33 and thereby increase its cytokine ac‐
tivity.27 In addition to their own allergens, HDM extracts can also 
contain IgE reactive bacterial products of S aureus or E coli derived 
from their natural microbiome.28	 Whether	 these	 products	 are	
proteases still needs to be elicited and it can only be speculated 
that they could have an adjuvant effect for HDM allergens. It was, 
however, shown that Der p 1 and Der f 1 degrade lung surfactant 
proteins A and D and thereby decrease the host's antimicrobial 
actions.29
2.2 | Fungal allergens as triggers for 
IL‐33 production
Several fungal serine proteases from Aspergillus spp, Penicillium spp, 
Curvularia lunata, A alternata, and others have been described as 
allergens30,31 (summarized in Table 1). Alternaria spp is a common 
outdoor mold but can also occur indoors in moldy dwellings.31 A al-
ternata exposure in children is associated with elevated IgE levels 
and higher airway IL‐33 levels. In mice, A alternata inhalation caused 
steroid‐resistant airway hyperreactivity, dependent on IL‐33.32 In 
humans, exposure to these fungal spores can lead to airway diseases 
such as allergic asthma, allergic rhinitis and sinusitis, allergic alveoli‐
tis, allergic pulmonary aspergillosis, or rhinosinusitis.31
Alternaria alternata extract induces allergic asthma via IL‐33 ac‐
tivation, dependent on the serine proteases in the extract.22,33 This 
further leads to activation of ILC2s and IL‐5 production which causes 
the maturation of eosinophils in the bone marrow in response to 
A alternata.34 Next to the serine protease activity in the A alternata 
extract, an aspartic protease of A alternata activates PAR2 and trig‐
gers degranulation of eosinophils.35 Contradicting data can be found 
concerning the importance of protease activity in asthma induction. 
While	heat‐inactivated	or	protease	inhibitor–treated	A alternata ex‐
tracts induce allergic asthma to the same extent as nondenatured 
extract in one study,36 another study shows that the protease activ‐
ity is necessary for the development of lung inflammation and PAR2 
activation.37
Aspergillus fumigatus has four different proteases, the metallo‐
protease Asp f 5, an aspartic protease Asp f 10, and two serine pro‐
teases Asp f 13 and Asp f 18.31 Asp f 5 and Asp f 13 deletion mutants 
showed reduced inflammatory cell recruitment and IL‐13 production 
compared to the wild type in a murine inhalation model; however, 
IgE levels and Th2 cytokine levels were comparable to the wild‐type 
treated mice.38 Asp f 13 disrupts the epithelial barrier and the extra‐
cellular matrix of airway smooth muscle cells, leading to airway hy‐
perreactivity in mice.39 Pen c 13, a serine protease from Penicillium 
citrinum, also increased epithelial permeability and allergic airway 
inflammation in mice.40,41
2.3 | Bacteria as a source of allergens with 
protease activity
The fungal allergens Cur l 1 from Curvularia lunata and Cla h 9 from 
Cladosporium herbarum are subtilisin‐like serine proteases.42,43 
Subtilisin (also called Alcalase) is a serine protease from Bacillus spp 
acting as a bacterial allergen, as it can induce specific IgE and IgG4 
formation, accumulation of eosinophils in the airway lumen and gob‐
let cell hyperplasia in mice. The active subtilisin triggers an early re‐
lease of amphiregulin, TSLP, IL‐1α, and IL‐33, while proteolytically 
inactive subtilisin cannot induce this response.44 IL‐33 is processed 
to a more bioactive cytokine by subtilisin.27 In humans, subtilisin 
and savinase, another Bacillus spp protease, cause specific IgE for‐
mation.45 These findings are of special interest, because detergents 
contain protein engineered mutants of subtilisin and other bacterial 
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proteases that have an increased stability. Some of these bacterial 
proteases are also used by the food industry.46
2.4 | Staphylococcus aureus proteases in type 2 
immune responses
Staphylococcus aureus possesses ten major secreted proteases in‐
cluding a serine protease (V8 protease), a metalloprotease (aure‐
olysin), two cysteine proteases (staphopain A and staphopain B), 
and six serine protease‐like proteins (SplA, SplB, SplC, SplD, SplE, 
and	 SplF).	 Spls	 are	 proteases	 encoded	 by	 the	 spl operon, located 
on the pathogenicity island vSab.47 The S aureus V8 protease and 
staphopains were shown to alter airway epithelial barrier integrity, 
modulate cytokine synthesis, and activate nuclear factor kappa‐
light‐chain	 enhancer	 of	 activated	 B	 cells	 (NF‐κB) in the airway 
epithelial cells, therefore predisposing to allergic sensitization.48 
Recently, it has been shown that the majority of nasal polyp tissue 
colonized with S aureus contained IgG binding to SplA, SplB, and 
SplD/F.4 Importantly, serum of asthmatic patients contained higher 
titers of SplA, SplB, SplD, and SplE‐specific IgE compared to controls 
suggesting their role in the pathogenesis of asthma.4 Moreover, SplD 
is produced by S aureus in measurable amounts in the airways of pa‐
tients with CRSwNP.11 Ex vivo nasal tissue explants produce IL‐5 in 
response to SplD and intratracheal applications of SplD in mice re‐
sult in induction of SplD‐specific IgE.4 All these data demonstrate 
that, next to their detrimental role in the airway epithelial barrier 
integrity, S aureus proteases act as allergens by inducing specific IgE 
response in humans and in mice.
SplD‐induced inflammation in mouse lungs is not accompanied 
by	 the	 release	of	TSLP,	 IL‐25,	or	GM‐CSF,5 which is in contrast to 
experimental models using other allergens with protease activity 
such as HDM and A alternata extracts.49,50 However, repeated in‐
tratracheal exposure of mice to SplD leads to a sustained produc‐
tion of IL‐33 in the lungs and the development of key features of 
TA B L E  1   Overview of allergens with proteolytic functions from different taxonomic kingdoms
Protease type Allergen name Origin species Class (kingdom) Reference
Cysteine Blo t 1 Blomia tropicalis Arachnida (animalia) 16
Serine Blo t 3, 6, 9 Blomia tropicalis Arachnida (animalia) 16
Cysteine Der f 1 Dermatophagoides farinae Arachnida (animalia) 16
Serine Der f 3, 6, 9 Dermatophagoides farinae Arachnida (animalia) 16
Cysteine Der p 1 Dermatophagoides pteronyssinus Arachnida (animalia) 16
Serine Der p 3, 6, 9 Dermatophagoides pteronyssinus Arachnida (animalia) 16
Serine nd Alternaria alternata Dothideomycetes (fungi) 22
Aspartic nd Alternaria alternata Dothideomycetes (fungi) 35
Serine Cla c 9 Cladosporium cladosporioides Dothideomycetes (fungi) 97
Serine Cla h 9 Claudosporium herbarum Dothideomycetes (fungi) 43
Serine Cur l 1 Curvularia lunata Dothideomycetes (fungi) 98
Serine Epi p 1 Epicoccum purpurascens Dothideomycetes (fungi) 99
Metallo‐ Asp f 5 Aspergillus fumigatus Eurotiomycetes (fungi) 38
Aspartic Asp f 10 Aspergillus fumigatus Eurotiomycetes (fungi) 31
Serine Asp f 13 Aspergillus fumigatus Eurotiomycetes (fungi) 38,39
Serine Asp f 18 Aspergillus fumigatus Eurotiomycetes (fungi) 31
Serine Asp fl 13 Aspergillus flavus Eurotiomycetes (fungi) 100
Serine Asp n 18 Aspergillus niger Eurotiomycetes (fungi) 100
Serine Asp o 13 Aspergillus oryzae Eurotiomycetes (fungi) 100
Serine Pen c 2 Penicillium citrinum Eurotiomycetes (fungi) 101
Serine Pen c 13 Penicillium citrinum Eurotiomycetes (fungi) 40
Serine Pen ch 13 Penicillium chrysogenum Eurotiomycetes (fungi) 41
Serine Pen ch 18 Penicillium chrysogenum Eurotiomycetes (fungi) 97
Serine Pen o 18 Penicillium oxalicum Eurotiomycetes (fungi) 43
Serine alcalase/subtilisin Bacillus subtilis Bacilli (bacteria) 44,45
Serine Esperase Bacillus licheniformis Bacilli (bacteria) 102
Serine Savinase Bacillus licheniformis Bacilli (bacteria) 45
Serine Spls	(A,B,D,E,F) Staphylococcus aureus Bacilli (bacteria) 5,103
nd, not determined.
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allergic asthma including eotaxin production, eosinophilia, bronchial 
hyperreactivity, goblet cell hyperplasia, and ILC2s infiltration of the 
airways.5
It has been shown that the release of IL‐33 upon exposure to 
SplD could exacerbate features of allergic asthma and contribute to 
an altered immune tolerance to other allergens. IL‐33 is sufficient to 
aggravate airway hyperresponsiveness and type 2 airway inflamma‐
tion in mice exposed to OVA12 or house dust mite.51 SplD mediates 
an IL‐33‐dependent sensitization to OVA.5 Likewise, increased lev‐
els of IL‐33 positively correlate with specific IgE to inhalant allergens 
and polyclonal sensitization in allergic children with severe refractory 
asthma.52
Initially, the mechanism of action of SplD in airway inflamma‐
tion in mice was mainly attributed to the increased expression of 
IL‐33 in airway epithelial cells type II and the activation of ILC2s, 
Th2 cells, and eosinophils.5 It was shown in the murine model of 
SplD‐triggered allergic asthma that neutralizing IL‐33 by sST2 ef‐
ficiently blocks SplD‐induced airway inflammation in mice as it sig‐
nificantly reduces the numbers of eosinophils, IL‐13+ ILC2s as well as 
IL‐13+ CD4+ T cells, and IL‐5 and IL‐13 production in the lung drain‐
ing lymph nodes.5 However, sST2 treatment does not significantly 
reduce the SplD‐induced airway hyperreactivity and airway remod‐
eling. Moreover, the adaptive immune response is crucial for the 
SplD‐induced airway inflammation because inflammatory changes 
are fully abrogated in the SplD treated Rag2−/− mice.5 Since ILC2 
population is preserved in Rag2−/− mice,53 it is conclusive that ILC2s 
are necessary but not sufficient for the induction of SplD‐induced 
inflammation. In the model of SplD‐induced airway inflammation, 
ILC2s have a rather supportive role via production of Th2 cytokines. 
It	is	important	to	mention	that	SplF	shows	94.6%	sequence	homol‐
ogy with SplD.54	In	mice,	SplF	induces	airway	inflammation	compa‐
rable to SplD.5 These data suggest a novel potent group of bacterial 
allergens present in S aureus.
However, we have shown that SplD does not directly acti‐
vate PAR2 and its downstream signaling in vitro, while in vivo 
PAR2 is increased in the SplD‐exposed lungs. This indicates an 
indirect activation of PAR2.5 Moreover, IL‐33 is an important 
regulator in the SplD‐induced PAR2 activation, since in mice 
treated with SplD and sST2, the levels of PAR2 in the lungs were 
significantly decreased.5 These data support the notion that en‐
dogenous proteases facilitate innate immune response induced 
by allergens.
2.5 | The role of proteases in the activation of IL‐33
Interleukin‐33 is one of the major cytokines in the regulation of the 
innate and adaptive immunity in the allergic airways.22,55,56 Repeated 
exposure to environmental factors and allergens with protease activ‐
ity triggers the activation of the airway epithelium and the release 
of TSLP, IL‐25 and IL‐33, which in turn triggers a sustained immune 
response in dendritic cells and ILC2s and activation of type 2 immune 
response.27,57,58 Once released, IL‐33 mediates its function upon 
binding to the ST2 receptor, a member of the Toll‐like/IL‐1 superfam‐
ily of receptors,59 widely expressed on ILC2s, Th2 cells, eosinophils, 
invariant natural killer T cells, natural killer cells, basophils, and mast 
cells.59‐63 IL‐33 binding to ST2 leads to the formation of a complex 
with the interleukin‐1 receptor, and a receptor accessory protein,64 
resulting in the recruitment of the adaptor protein MyD88.65 This re‐
cruitment activates the interleukin‐1 receptor‐associated kinase‐1,‐4, 
mitogen‐activated	protein	kinase,	and	TNF	receptor‐associated	fac‐
tor‐6,	which	results	in	the	activation	of	NF‐κB, p36, and the protein 
kinase c‐Jun N‐terminal kinases.59
Unlike other members of the IL‐1 family, such as IL‐1β and IL‐18, 
IL‐33 does not require caspase‐1 cleavage for its activation.66 IL‐33 
is inactivated by caspase‐3‐ and caspase‐7‐mediated cleavage of its 
cytokine domain during apoptosis.67 It is known that the activity of 
IL‐33 is regulated by endogenous proteases released during inflam‐
mation from epithelial cells, neutrophils, and mast cells. Endogenous 
proteases such as neutrophil elastase or cathepsin G were shown to 
activate IL‐33 during bacterial, fungal, or viral infections.68 Cleavage 
of IL‐33 by mast cell tryptase results in the generation of shorter 
mature forms of IL‐33. Mature IL‐33 is up to 30‐fold more potent 
than the full‐length IL‐33 in its capacity to induce an expansion of 
ILC2s and Th2 cells, next to their IL‐5 and IL‐13 production.62 There 
are inconsistent data concerning the activation or degradation of 
IL‐33 by human mast cell chymase.62,69 The murine mast cell chy‐
mase mMCP‐4 has been shown to degrade IL‐33.69,70	When	IL‐33	is	
incubated with allergens that have protease activity, it gets cleaved 
in its central cytokine domain, generating a shorter and more active 
form of IL‐33, which efficiently activates ILC2s, basophils, mast cells, 
and eosinophils.27 Therefore, IL‐33 acts as a sensor for aeroallergens 
with proteases activity to trigger the downstream inflammatory 
cascade.27
It has been shown that the oxidation state of IL‐33 affects the 
binding capacity of IL‐33 to ST2.71 Oxidized IL‐33 is most commonly 
found in the sputum from exacerbating asthmatics, which could 
be an intrinsic mechanism to limit an extensive inflammation. Both 
forms of IL‐33, oxidized and reduced, are found during disease exac‐
erbations in sputum of patients with moderate and severe asthma.71 
Endogenous calpains, from damaged airway epithelial cells, can 
process full‐length IL‐33 and increase its alarmin activity up to 
~60‐fold.72
It is important to point out that several alternatively spliced vari‐
ants of IL‐33 were detected in asthmatic patients.73 Among them, 
an IL‐33 isoform lacking exons 3 and 4, that was shown to have a 
cytoplasmic localization in airway epithelial cells, could be actively 
secreted and activate mast cells and basophils.73 In asthmatic pa‐
tients, this isoform is strongly associated with type 2 biased airway 
inflammation.73
In CRSwNP mucosa, S aureus induces epithelial cell‐derived re‐
lease of IL‐33 and TSLP via cell wall compartment‐induced TLR2 ac‐
tivation.15 However, it has been shown that SplD does not activate 
TLR2 directly5 suggesting that other recognition mechanisms are in 
place.
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2.6 | Endogenous protease inhibitors in the airways
Natural protease inhibitors exist for serine, cysteine, metallo‐, and 
aspartic proteases.74 Cystatin A is a cysteine protease inhibitor, 
and in combination with the serine protease inhibitor Kazal‐type 
5 (SPINK5), it is involved in the regulation of the innate cytokine 
(IL‐25, IL‐33, and TSLP) response of A alternata extract or S aureus 
V8 protease, when exposed to human bronchial epithelial cells. In 
eosinophilic CRSwNP, the expression of cystatin A and SPINK5 is 
decreased compared to nasal tissue of noneosinophilic CRS.75
These findings underline the importance of antiprotease activ‐
ity in the nasal mucosa for the prevention of detrimental effects 
of exposure to environmental allergens with protease activity and 
provide a possible explanation for the reduced capacity of epithe‐
lium to counteract the protease activity in CRSwNP, resulting in a 
sustained chronic type 2 inflammation. The role of this antiprotease 
network still needs to be discovered in the regulation of Spls’ activity 
in chronic airway inflammation.
α1‐Antitrypsin (A1AT) inhibits trypsin, KLK7, KLK14, neutrophil 
elastase, proteinase 3, and matriptase. It is an acute‐phase protein 
with a high abundance in serum. Apart from inhibiting neutrophil 
proteases, A1AT also inhibits the migration and activation of neu‐
trophils,76 next to preventing the proteolytic maturation of matrix 
metalloproteinase‐9 (MMP‐9) by serine proteases from German 
cockroach extract.77 IL‐6 and to a lesser extent LPS, tumor necrosis 
factor‐α	 (TNF‐α), and IL‐1β stimulate A1AT secretion from mono‐
cytes.78 Proteome analysis of nasal secretion from allergic rhinitis 
(AR) patients and healthy controls revealed 2.5‐fold higher levels of 
A1AT in AR patients.79 The mast cell chymase mMCP‐1 can be inhib‐
ited by A1AT1, A1AT2, and A1AT4 in the serum.80
Serine protease inhibitor B1 is produced by neutrophils and in‐
hibits the neutrophil proteases elastase, cathepsin G, and protein‐
ase‐3. In a lung‐infection model of Pseudomonas aeruginosa with 
SERPINB1‐deficient mice, SERPINB1 proved to be an important 
factor for the survival, bacterial clearance, and SP‐D degradation.81
Furthermore,	 serum	 levels	 of	 SERPINB3	 and	 SERPINB4	 are	
increased in asthma, chronic obstructive pulmonary disease, and 
atopic dermatitis patients. SERPINB3 inhibits cathepsins S, K, L, and 
papain, while SERPINB4 inhibits mast cell chymase, cathepsin G, 
granzyme M, and Der p 1. IL‐4 and IL‐13‐stimulated bronchial ep‐
ithelial cells upregulate these two serpins. In mice, serpinb3a also 
inhibits papain, Der p 1 and the cathepsins S, K, L, and G, as well as 
V. The activation of serpinb3a is dependent on IL‐13 as IL‐13‐treated 
serpinb3a‐deficient mice have a significantly diminished inflamma‐
tory response. In an allergic asthma model, HDM‐treated serpinb3a‐
deficient BALB/c mice developed a similar eosinophilic response as 
the wild‐type mice, but have a decreased mucus production.82
Genetic variations within proteases and their inhibitors have 
also been associated with asthma, atopy, or chronic inflammatory 
lung	diseases.	For	example,	two	polymorphisms	of	the	MMP9	gene	
are associated with childhood atopic asthma risk, one of which 
upregulates the expression levels of MMP9.83 A polymorphism 
downstream of mast cell chymase gene (CMA1) is associated with 
bronchial asthma, atopic asthma, and IgE levels.84,85	Furthermore,	
one polymorphism in the promoter region of CMA1 is associated 
with atopic eczema.86 The variability in copy number of human 
α‐tryptase can also have an impact on total and HDM‐specific 
IgE levels in asthmatic patients. Patients carrying one copy of α‐
tryptase had lower IgE levels and worse lung function, but two 
copies correlated with higher total and HDM‐specific IgE lev‐
els.87 Interestingly, α‐tryptase is suggested to be enzymatically 
inactive.88 Hereditary loss of α1‐antitrypsin/SERPINA1 results in 
early‐onset chronic obstructive pulmonary disease and emphy‐
sema.89 A downstream mutation in serine protease inhibitor A3 
(SERPINA3) has been identified as a possible susceptibility locus 
for childhood asthma.90 Interestingly, cystic fibrosis patients defi‐
cient of α1‐antichymotrypsin/SERPINA3 have significantly milder 
symptoms of lung inflammation than non‐α1‐antichymotrypsin de‐
ficient patients.91
Whether	 there	 is	 a	 possible	 link	 of	 serine	 protease	 inhibitor	
production with the susceptibility of chronic inflammatory airway 
disease development upon S aureus colonization still needs to be 
investigated.
2.7 | Interference with the ST2/IL‐33 signaling axis 
for therapeutic purposes
Blocking of the IL‐33 pathway by different pharmacological 
and genetic tools can be a promising and an efficient strategy 
to inhibit inflammatory changes induced by different groups of 
allergens. Indeed, the critical role of IL‐33 in the initiation and 
modulation of allergic airway disease has been already proven 
(Table 2). Next to IL‐33 blocking or IL‐33 neutralizing antibod‐
ies, sST2 is an elegant way to inhibit the IL‐33 signaling pathway. 
sST2 functions antagonistically to IL‐33, acting as a decoy recep‐
tor and preventing IL‐33 from binding to the membrane bound 
isoform ST2, thereby inhibiting its effector function.92,93 Anti‐
IL‐33 antibodies as well as sST2 were shown to be efficient in re‐
duction of the most prominent features of murine OVA‐induced 
allergic asthma models such as eosinophil counts and IL‐4, IL‐5, 
and IL‐13 in bronchoalveolar lavage fluid.94,95 Airway hyperreac‐
tivity to methacholine was also efficiently downregulated by this 
treatment in mice. However, the relatively short half‐life of exist‐
ing pharmacological compounds for binding active IL‐33 does not 
allow the full prevention of airway remodeling and specific IgE 
production when using these compounds in the therapeutic regi‐
mens in a murine model of asthma, for example, induced by SplD5 
or combination of HDM and diesel exhaust particles.96 A phase 
1 clinical study to evaluate the safety and tolerability of a single 
dose of anti‐IL‐33R antibody (CNTO 7160) in healthy participants 
and multiple doses in participants with asthma and atopic derma‐
titis has been completed; however, no results have been reported 
yet. All these studies indicate that interference with the IL‐33/
ST2 signaling axis is a very promising strategy in preventing type 
2 inflammation in diseases like CRSwNP and asthma induced by 
bacterial allergens.
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3  | CONCLUDING REMARKS AND FUTURE 
PERSPEC TIVES
In this review article, we underlined that the IL‐33/ST2 signaling 
axis is activated in response to the major inhaled allergens from 
fungi, mites, and bacteria and highlighted the role of protease/anti‐
protease network in balancing the activity of exogenous proteolytic 
enzymes. Therefore, both signaling pathways represent potential 
targets for the future therapeutic interventions to prevent severe 
chronic type 2 biased airway inflammation. Deeper understanding 
of the interaction of S aureus‐secreted compounds and subsequent 
immune responses in the host might help to understand how colo‐
nization of S aureus or exposure due to inhaled S aureus compounds 
can bias toward type 2 immune response in asthma and CRSwNP. 
Identification of these complex interactions between S aureus and 
the immune system may lead to the development of novel efficient 
therapeutics to prevent an exuberant activation of the immune 
system induced by pathogenic germs colonizing mucosal surfaces. 
It is important to state that many questions remain regarding the 
predisposition to a conversion of commensal S aureus lifestyle into 
pathologic colonization. It remains to be analyzed whether S au-
reus proteins contribute to initiation and acute exacerbations of 
human asthma and CRSwNP in the same way as shown in mice. 
Answers to these remaining questions will eventually provide us 
with the necessary insights on how to modulate either S aureus and 
its proteases or the host response in order to treat chronic type 2 
diseases when other treatment strategies fail.
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TA B L E  2   The role of different IL‐33 targeting strategies on inflammatory changes in mouse models of allergic asthma
 Allergen AHR
Inflammatory 
infiltration of lungs Th2 cytokines/chemokines IgE response References
IL‐33 knockout OVA ns ↓	Eosinophils ↓	IL‐4,	IL‐5,	IL‐13,	CCL‐11,	
CCL‐5, CCL22, CXCL2
ns 104
OVA/ aluminum 
hydroxide
↓	AHR ↓	Eosinophils ns ns 105
HDM na ↓	Eosinophils na na 105
Papain na ↓	Eosinophils na na 105
ST2 knockout HDM ↓	AHR ↓	Eosinophils ↓	IL‐4,	IL‐5,	IL‐13,	IL‐33,	
GM‐CSF,	IL‐1b,	TSLP,	MCP‐1
↓ 106
OVA na ↓	Eosinophils ↓	IL‐4,	IL‐5,	IL‐13,	CCL‐11,	
CCL‐5, CCL22, CXCL1, CXCL2
↓ 107
Alternaria alternata na ↓	Eosinophils ↓	IL‐5	ns	IL‐13 na 33
IL‐33 neutral‐
izing 
antibodies
OVA na ↓	Eosinophils ↓	IL‐4,	IL‐5,	IL‐13 ↓ 108
ST2 blocking 
monoclonal 
antibodies
OVA ↓AHR na ↓	IL‐4	ns	IL‐13 na 109
sST2 soluble 
receptor
OVA na na ↓IL‐4,	IL‐5,	IL‐13 na 95
OVA na ↓	Eosinophils ↓	IL‐4,	IL‐5, na 110
OVA‐DCs na ↓	Eosinophils na na 111
HDM na ↓	Eosinophils ns ↓	Total	IgE 49
S aureus SplD ↓	AHR ↓	Eosinophils ↓	IL‐4,	IL‐5,	IL‐13 ↓	Total	IgE	ns	
specific IgE
4,5
DCs, dendritic cells; HDM, house dust mite; IgE, immunoglobulin E; na, not analyzed; ns, not significant; OVA, ovalbumin.
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